Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 36Recurrence 5Neoplasms, Plasma Cell 3Immunoglobulin Light-chain Amyloidosis 3Amyloidosis 2Plasmablastic Lymphoma 1

Interventions

Dexamethasone 4Cyclophosphamide 4Bortezomib 3daratumumab 2belantamab mafodotin 2venetoclax 1pegfilgrastim 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Lenalidomide 1Calcium Dobesilate 1Antineoplastic Protocols 14-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Amyloidosis × belantamab mafodotin × 1 year × Clear all
NCT05145816 2026-05-07

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡